Breast Cancer: Zoledronic Acid Every 12 Weeks Non-inferior to Every 4 Weeks

Share this content:
Zoledronic acid receipt every 12 weeks may be non-inferior to infusion every 4 weeks for patients with bone-metastatic breast cancer.
Zoledronic acid receipt every 12 weeks may be non-inferior to infusion every 4 weeks for patients with bone-metastatic breast cancer.

Zoledronic acid receipt every 12 weeks may be non-inferior to infusion every 4 weeks for patients with bone-metastatic breast cancer, according to a study published in JAMA Oncology.1

Infusion of zoledronic acid, a bisphosphonate, is recommended for patients with bone metastases from solid and hematologic cancers to reduce the frequency of skeletal-related events (SREs). There is, however, a paucity of data about the efficacy and safety of this treatment for patients with breast cancer, who can live with bone metastases for longer than 1 year. One concern is whether frequent administration over a long period will result in accumulation of the drug within the bone.

For this randomized trial (ClinicalTrials.gov Identifier: NCT00320710), researchers evaluated the safety and efficacy of a second year of zoledronic acid treatment. Of 416 patients enrolled, 200 patients were assigned to treatment every 4 weeks, 203 were assigned to treatment every 12 weeks, and 13 were assigned to placebo. The placebo arm was, however, eliminated after the approval of bisphosphonates.

Twenty-two percent of patients in the 4-week group had at least 1 SRE vs 23% in the 12-week group. There was no significant difference in SRE-free survival.

In both groups, 189 patients had at least 1 adverse event. Among common adverse events, fatigue was more common in the 12-week group, while arthralgia, nausea, and back pain were more common in the 4-week group.

RELATED: Bone-metastatic Cancer: Zoledronic Acid and Skeletal Events

The authors concluded that 12-week administration of zoledronic acid is non-inferior to 4-week administration among patients with breast cancer who complete at least 9 doses of bisphosphonate treatment.

Reference

  1. Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jan 26. doi: 10.1001/jamaoncol.2016.6316 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters